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The 2019 Havemeyer Workshop brought together researchers and clinicians to discuss the latest 33 
information on Equine Asthma and provide future research directions. Current clinical and molecular 34 
asthma phenotypes and endotypes in humans were discussed and compared to asthma phenotypes in 35 
horses. The role of infectious and non-infectious causes of equine asthma, genetic factors and 36 
proposed disease pathophysiology were reviewed. Diagnostic limitations were evident by the limited 37 
number of tests and biomarkers available to field practitioners. The participants emphasized the need 38 
for more accessible, standardized diagnostics that would help identify specific phenotypes and 39 
endotypes in order to create more targeted treatments or management strategies. One important 40 
outcome of the workshop was the creation of the Equine Asthma Group that will facilitate 41 
communication between veterinary practice and research communities through published and easily 42 
accessible guidelines and foster research collaboration. 43 
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Introduction 49 
The effort to clarify the phenotype and terminology used to characterize horses with chronic 50 
inflammatory airway disease started in 2000 with a workshop in East Lansing, Michigan.(1) Several 51 
workshops were subsequently held with similar goals in mind with the latest hosted in Cabourg, 52 
France in 2014.(2) In the last few years, the terminology has further evolved with the term equine 53 
asthma (EA) now being recommended to describe horses with chronic respiratory signs ranging in 54 
severity from mild to severe that were previously referred as inflammatory airway disease  and 55 
recurrent airway obstruction, respectively.(3) Although strong evidence supports the role of exposure 56 
to environmental dust in the pathophysiology of both mild and severe EA, the potential role of 57 
infectious agents (bacterial and viral) has not been clearly established. 58 
The goal of the 2019 Havemeyer Workshop on Equine Asthma was to bring together researchers and 59 
clinicians from different disciplines who are actively investigating airway inflammation to discuss 60 
the latest information on this topic and provide some comparative perspective from human asthma. 61 
The workshop was designed to facilitate productive discussions that would inform potential future 62 
revisions of the 2016 American College of Veterinary Internal Medicine (ACVIM) Consensus 63 
Statement on mild-moderate EA(3) and provide future research directions.  64 
The present report follows the format of the workshop. The manuscript is organized thematically 65 
starting with the recent advancements in the understanding of the classification and diagnosis of 66 
human and equine asthma. The second part is centered on the etiology and pathophysiology of EA. 67 
The third and final section of the manuscript summarizes the extensive discussions conducted during 68 
the workshop with the goal of prioritizing future directions of EA research.  69 
  70 
 71 
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Clinical and molecular phenotypes of human asthma – James Martin 72 
Clinical asthma phenotypes have been recognized for many decades but were collapsed into a unified 73 
hypothesis of asthma as an allergic disease in 1989 when age adjusted levels of immunoglobulin E 74 
were associated with asthma. It has taken more than 20 years to consider the heterogeneity of asthma 75 
again with an emerging emphasis on endotypes, an intrinsically more interesting approach to 76 
understanding asthma pathobiology.(4) The term "endotype" is used to describe a subtype of disease 77 
defined by a molecular mechanism, genetic variation or by treatment response.(5,6) Cluster analyses 78 
of asthma cohorts have revealed groups with different ages of onset, lung function, concordance or 79 
lack thereof between measures of airway inflammation by sputum analysis and symptoms. A recent 80 
review of asthma by a panel of experts has focused on the need to recognize asthma in its diverse 81 
forms and to identify treatable traits. This extensive review has highlighted areas for future 82 
attention.(7)  83 
The application of the analysis of gene expression to airway epithelial cells and sputum cells from 84 
well-characterized groups of asthmatics has led to the appreciation of asthma associated with T 85 
helper 2 cytokines and non-T2 asthma.(8) The former is the more allergic subset with higher IgE and 86 
peripheral and sputum eosinophilia. Non-T2 asthma has fewer of these features and is less responsive 87 
to inhaled corticosteroids. T cells that express interleukin-17 have been linked to severe neutrophilic 88 
asthma. These so-called Th17 cells have been shown in animal models to be associated with steroid-89 
unresponsiveness. The Th1 cytokine interferon-γ likewise has been found to be expressed in the 90 
airways of severe asthmatics. 91 
In recent years there has emerged another lymphoid cell that participates in host responses to mucosal 92 
injury. These innate lymphoid cells are lineage negative, lacking the usual lymphocyte surface 93 
markers.(9) They express similar panels of cytokines to the T helper subsets and are labelled innate 94 
lymphoid cell (ILC) 1, 2 and 3. They are rapidly activated by epithelial signals such as thymic 95 
stromal lymphopoietin (TSLP), interleukins 25 and 33, molecules termed alarmins. The secretion of 96 
IL-5 and IL-13 by ILC2 may lead to a pattern of inflammation previously interpreted as Th2. Innate 97 
lymphoid cells are less steroid sensitive. Additionally, alarmins prime cells such as dendritic cells 98 
and therefore may have a role in adaptive immunity as well as innate immune responses. The 99 
synthesis of amphiregulin, an epidermal growth factor receptor ligand, by ILC2s but also Th2 cells, is 100 
postulated to promote mucosal integrity. One could anticipate that viral infection of epithelial cells or 101 
damage by irritants giving rise to inflammation mediated by ILCs. However, their roles have yet to 102 
be fully explored.  103 
Transcriptomic analysis of sputum has revealed three patterns of inflammation and gene signatures 104 
consistent with both Th2 and ILC2 driven inflammation and oxidative stress.(10) The descriptions of 105 
molecular mechanisms of inflammation may still be considered as a deeper form of phenotyping. 106 
However, the application of novel biologics to treat asthma is now implicating certain pathways in 107 
disease and therefore is providing us with true disease endotypes. Most of the progress in the 108 
identification of treatable traits has related to the T2 phenotype.  Biologics targeting IgE 109 
(omalizumab), IL-5 and therefore, the eosinophil (mepolizumab, benrazilumab, rezlizumab) and the 110 
T2 cytokines (dupilumab) have all demonstrated efficacy in reducing exacerbations of asthma.  111 
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Recent results of studies targeting the alarmin TSLP and therefore both T2 high and low asthma have 112 
confirmed efficacy against acute attacks of asthma.  Oxidative stress in asthma has not been 113 
specifically addressed.  A problematic form of asthma is that associated with airway remodeling and 114 
fixed airway obstruction.  The association with mucus plugging and eosinophilic inflammation has 115 
been recently identified as a potential factor in long term impaired airway function.(11) 116 
Severe equine asthma is typically a neutrophilic form of asthma although expression of T2 cytokines 117 
has been described.(12) There is also evidence that IL-17 is expressed in equine asthma and its 118 
effects on neutrophil survival are steroid-insensitive.(13,14) Although neutrophilic human asthma is 119 
less steroid-sensitive than the eosinophilic phenotype, severe equine asthma is responsive to steroid 120 
treatment despite the presence of neutrophilic inflammation.  Severe equine asthma shares the 121 
structural remodeling of the airways with human asthma and a part of the remodeling change is 122 
reversible with steroid treatment as well as withdrawal from the inciting stimulus.(15) Studies of 123 
airway remodeling in human asthma with treatment have not addressed key components of 124 
remodeling such as increased airway smooth muscle mass. 125 
Clinical phenotypes of equine asthma – Jean-Pierre Lavoie 126 
The purpose of the 2007 ACVIM Consensus Statement on mild-moderate EA was to review the 127 
current knowledge and opinions concerning this condition and to help practitioners differentiate 128 
mild-moderate EA from severe EA.(16) The consensus was revised in 2016 and discussed the use of 129 
EA to describe these conditions.(3) The revised consensus recognized that asthmatic horses of all 130 
severities have common clinical presentations (such as chronic cough, excess mucus, poor 131 
performance) but also a wide heterogeneity in terms of triggering factors, severity, and pathologic 132 
characteristics.  133 
A phenotype is the observable physical properties of an organism, including measurable laboratory 134 
findings, which is the result of the expression of the genes in response to the environment.(17) 135 
Identifying distinct phenotypes is of interest if they facilitate the diagnosis, the prognosis or allow the 136 
implementation of targeted therapy. While currently loosely defined, the EA phenotypes discussed in 137 
the 2016 Consensus statements were based on clinical presentation (severe versus mild/moderate), 138 
triggering factors (barn/hay or pasture), endoscopy findings (mucus) and bronchoalveolar cytology.  139 
From a clinical standpoint, further dividing EA as distinct "mild" and "moderate" phenotypes may 140 
promote recognition that asthma is an underdiagnosed cause of exercise intolerance in high 141 
performance horses. Horses with a cough or increased respiratory rate at rest or following exercise 142 
will commonly undergo further diagnostic procedures to confirm asthma, or “anti-asthma” treatments 143 
will be implemented. However, this is generally not the case when no clinical signs suggestive of an 144 
airway disease are present. The term "mild EA" could describe the condition affecting these horses, 145 
while "moderate EA" would be used when clinical signs of airway disease (such as cough) are 146 
present, but without the periods of labored breathing at rest seen in "severe EA".(18) The 147 
inflammatory airway cell phenotypes (neutrophils, mast cells, eosinophils) were recognized in the 148 
2007 and 2016 consensus statements.(3,16) Future phenotypes may include the age (early or late) of 149 
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appearance of clinical signs, or specific remodeling features affecting the airways, if these new 150 
features are shown to facilitate prognostication or the implementation of specific therapy. 151 
The future development of new portable and sensitive devices for measuring the lung function of 152 
horses (forced oscillation or flow interruption techniques), or the discovery of blood biomarkers for 153 
EA would help not only to facilitate the diagnosis of mild and moderate forms of EA in clinical 154 
practice, but also to possibly identify new phenotypes for these conditions. 155 
(5,6)To date, different inflammatory pathways have been proposed as contributing to EA, which may 156 
eventually lead to novel therapies.(19) The discrepancies between results of the different studies may 157 
be an indication of different endotypes in EA, although future studies on large cohorts of horses from 158 
multiple sites would be required before specific endotypes can be recognized. Multicenter tissue 159 
banking could facilitate these studies.  160 
In summary, the 2016 ACVIM Consensus Statement recognized the currently known distinctive 161 
features of EA. Further defining "mild" and "moderate" EA based on the presence or absence of 162 
easily identified clinical signs may promote the investigation of the subclinical (mild) phenotype. The 163 
identification of novel phenotypes and endotypes may lead to "precision medicine" where treatments 164 
most likely to help equine patients would be selected. This approach is now implemented in humans 165 
and may eventually be applicable to horses if supported by scientific research. 166 
 167 
Summer pasture-associated severe equine asthma: phenotype and triggers - Cyprianna 168 
Swiderski 169 
Severe equine pasture asthma (EPA) is characterized by episodes of reversible airway obstruction in 170 
horses grazing pasture during the summer in hot humid climates.(20) Affected horses demonstrate 171 
neutrophilic airway inflammation, airway hyper-responsiveness extending throughout the season of 172 
remission, and airway remodeling.(21,22) The author’s experience is restricted to EPA as first 173 
described in horses residing in Louisiana, and diagnosed in states with subtropical climates 174 
(Mississippi, Alabama, and Florida).(20) Veterinarians in regions of adjoining states and distant 175 
states (Oregon) describe similar signs in horses grazing pastures during hot humid conditions. EPA is 176 
described in the United Kingdom where it differs in its association with hot dry weather or exposure 177 
to dust from harvest/burning of crops.(23) EPA demonstrates adult onset (12 ± 6 years; range 1-29 178 
years) without sex predilection.(24) Asthma exacerbations generally begin in summer (July), 179 
persisting until temperature and humidity decrease (October/November).(25) Fewer horses 180 
experience asthma in the spring. A history of prior seasonal cough and/or exercise intolerance may be 181 
identified. Improvement within hours to days of isolation from pasture particulates in a stall 182 
environment is a key diagnostic feature of EPA in the southeastern USA;(20) some severe cases 183 
necessitate isolation in a climate climate-controlled environment. In the author’s experience, without 184 
adequate environmental management, disease severity is progressive and responsiveness to parenteral 185 
corticosteroids decreases.  186 
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Though specific agent(s) that elicit EPA exacerbation are not identified, the response to stall housing 187 
implicates seasonal pasture-associated particulates. Costa et al. reported increases in grass but not 188 
tree pollens were significantly associated with EPA exacerbation using a pollen station ~90 miles 189 
from affected horses.(25) In this regard, intact pollen is too large to reach the respirable zone of 190 
humans in order to elicit asthma, but moist conditions that are associated with EPA exacerbations can 191 
shatter pollen and disseminate respirable particles.(26) Grass pollen sensitization is classically 192 
associated with Th2 responses, IgE-mediated hypersensitivity, and eosinophilic inflammatory 193 
infiltrates. However, chronic exposure to Th2 sensitizing antigens and to complex antigen 194 
combinations that include Th2 sensitizing antigens each generate Th17 responses accompanied by 195 
neutrophilic airway inflammation that typifies EPA.(27,28)  196 
Subtopical grasses differ substantially from grasses in temperate and continental climates.(29) Pollen 197 
from subtropical grass subfamilies is important to rhinitis and human asthma in subtropical zones of 198 
Australia, Asia, India, Africa, and America. Pollination seasons for Bahia and Bermuda grass (spring 199 
through September/October) align to the season of EPA exacerbation.(30,31) The pollen season for 200 
Johnson grass is temperature dependent, flowering from May to July, with higher temperatures 201 
moving flowering later into Autumm.(32)  202 
A role for fungal triggering in EPA exacerbation is suggested by the near identical clinical picture 203 
presented by horses with EPA and barn dust-associated severe asthma, wherein a role for fungal 204 
triggering is substantiated in the latter.(33) Chronic neutrophilic airway inflammation characterizing 205 
both forms of severe equine asthma also aligns to Th17-mediated neutrophilic inflammation in fungal 206 
asthma models.(34) Of the more than 100 species of fungi that exist in biotropic relationships with 207 
Bermuda, Bahia, and Johnson grasses, Curvularia, Helminthosporium, Alternaria, Puccinia, 208 
Epicoccum, and Fusarium are implicated in eliciting human asthma.(35) Costa et al. identified fungal 209 
spores of the genus Nigrospora, and Curvularia, as well as basidiospores, as temporally associated 210 
with exacerbations of pasture asthma.(25) These findings are in agreement with reported correlations 211 
between EPA exacerbation and high dew point temperature.(25) Specifically, Nigrospora conidia 212 
and basidiospore release increase with increasing relative humidity, resulting in a peak in spore 213 
counts during the early morning and aligning to the association of EPA exacerbations with increased 214 
dew point temperature.(25,36) In contrast, conidia of Cladosporium, Alternaria, Epicoccum, and 215 
Dreschlera spp are released during warm, dry, windy conditions, while precipitation is required for 216 
release of many ascospores. In this way, humidity influences fungi of relevance to asthma in different 217 
locales which could influence associations of pasture asthma in the UK with hot dry conditions, 218 
rather than hot humid conditions precipitating pasture asthma in the southeastern US.  219 
As a chronic and progressive disease of undetermined etiology, EPA is most effectively managed by 220 
segregation from inciting grass pastures during warm seasons. The necessity to segregate horses from 221 
pasture, particularly at a time when they are typically extensively ridden and grazed, presents a 222 
conundrum that is ultimately detrimental for most affected horses. Accordingly, there is a critical 223 
need to identify the agents that trigger EPA in order to improve disease management.  224 
 225 
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Recommended minimum database for diagnosis of equine asthma by equine practitioners in 226 
the field vs. criteria used for research – Melissa Mazan 227 
Both veterinary practitioners and researchers muse about the diagnostic armamentarium available to 228 
physicians – if only we had the chest CT, the advanced lung function testing, the biomarkers – then 229 
we would be able to have a better diagnosis. A quick search of the literature, however, shows us that 230 
our counterparts face many of the same diagnostic dilemmas that we do, albeit often with higher 231 
bills! While pulmonologists have drawn up multiple guidelines to help in the diagnosis of asthma in 232 
humans with its multiple phenotypes and endotypes, physician-diagnosed asthma criteria often fail to 233 
be consistent with the official guidelines rendering the results of large epidemiologic studies or 234 
clinical trials fraught with the perils of resting findings on nebulous datasets. Various forms of 235 
spirometry or simple pulmonary function testing are readily available in human medicine, but few 236 
non-pulmonologists avail themselves of objective data, and instead rest on reported symptoms such 237 
as difficulty breathing on exertion, cough or positive response to bronchodilation.(37) Indeed, the 238 
GINA toolbox identifies “lack of access to spirometry/bronchoprovocation tests” as a barrier to 239 
implementation of GINA guidelines in human asthmatics.(38)  Moreover, the heterogeneity in 240 
published algorithms for diagnosis of asthma – more than 66 in the literature at last count – make 241 
even an algorithm-based diagnosis unsure.(39) Thus, the conclusion that symptom-based diagnosis is 242 
associated with a significant risk of over-diagnosis has been reached for asthma in humans.(40) The 243 
current push in human medicine to refine both the phenotypes and endotypes for multiple different 244 
subtypes of asthmas aims to elucidate the underlying causes and thus treatments that may be very 245 
different. We are still searching for the criteria that will help us with this in equine medicine. If there 246 
are indeed mechanistically different groups of horses within the categories of mild, moderate, and 247 
severe EA that are associated with genetic differences or cellular or molecular biomarkers, then 248 
perhaps we will gain better understanding of treatment successes and failures and will be able more 249 
logically to choose clinical therapies and predict responses.  250 
The difficult case for the clinician and the researcher alike is not the horse with severe EA – because 251 
the history and clinical exam alone can often suffice to diagnose, and there is a visible relief in 252 
respiratory embarrassment with administration of bronchodilator (although it can take some time in 253 
horses with diaphragmatic exhaustion).(41) The difficult horse is the one with moderate/severe 254 
asthma in remission and the horse with mild-moderate EA. As was recently pointed out, the biggest 255 
difference that we note in the clinical diagnosis of horses with mild-moderate EA v. severe EA is the 256 
presence of an increased respiratory effort at rest, which is due to the underlying pathophysiology of 257 
bronchoconstriction, increased mucus, and bronchiolar inflammation.(42) The need, then, is to detect 258 
the mildly or subclinically affected horse.  259 
As veterinarians, we have at hand history, clinical signs, lung function testing, radiographs, 260 
endoscopy, analysis of airway secretions, blood biomarkers and clinical pathology which can be used 261 
in a minimum database in order to classify horses into clinically useful categories that have a 262 
pathophysiologic basis that can simultaneously allow us to diagnose, treat, and translate clinical cases 263 
into field research. 264 
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History: A tentative diagnosis of EA in its most severe form can often be made on history alone, with 265 
the key component being the recognition of episodes of reversible respiratory embarrassment 266 
precipitated by exposure to specific triggers – namely, moldy hay in the northeast of the United 267 
States, and pasture allergens and particulates in the south. History in subclinical or mild cases is 268 
seldom of such definitive use; this does not mean that it is unimportant. Such questions as 269 
parentage,(43) type of feed and how it is fed,(44) and heat and pollen counts at the time of 270 
diagnosis(45) may be important risk factors for equine asthma. While it has been proposed that 271 
coughing and poor performance may serve to define a phenotype of moderate vs. mild EA,(46) these 272 
signs are not sufficiently sensitive(47) and would misclassify a subset of horses - they alert the 273 
clinician that moderate EA is likely, but the absence of these signs does not rule out disease. The 274 
connections between EA and viral or bacterial disease are not linear, but it is becoming increasingly 275 
clear that the connection exists,(48,49) thus a thorough history should include probing for past 276 
infectious respiratory disease. One of the best described questionnaire analysis tools for classification 277 
of horses based on history is the HOARSI index,(50) developed as a means of distinguishing among 278 
normal, mild-moderate EA or severe EA phenotypes. However, clinical signs and indices are 279 
insufficiently sensitive to distinguish horses with mild-moderate EA from normal horses or horses 280 
with severe EA in remission.(51) 281 
Proposed minimum database for both practitioners in the field and for research: A common history 282 
tool should be developed that addresses the main concerns of parentage if known, current and 283 
lifetime exposures to particulates and allergens including feeds and feeding practices, barn 284 
environment, vaccinations, travel history, and recent illnesses.  285 
Clinical scoring/clinical presentation: Multiple scoring systems have been shown to be useful for 286 
distinguishing healthy horses from horses with severe EA in exacerbation, but, similar to 287 
questionnaire indices, these scoring systems do not help in the more difficult problem of 288 
distinguishing horses with mild EA from healthy or severe EA in remission.(52) Indeed, 19 years 289 
ago, Robinson et al. found that even in horses with historical severe EA, clinical score failed to 290 
reflect low-grade airway obstruction, and suggested that without easily used, field-accessible testing 291 
equipment, lower airway disease would go underdiagnosed.(53) Recently, the adapted 23-point 292 
scoring system has been shown to be the most useful in discriminating mild from severe cases, but it 293 
is unlikely to distinguish normal from subclinical disease(54) , and the IDEASS scoring system has 294 
recently been described as a useful scoring system for moderate-to-severe equine asthma.(55) Thus, 295 
while clinical scoring is essential to a good examination and careful research, and can potentially be 296 
useful in measuring response to treatment in the individual, it is insufficient in making the phenotypic 297 
distinction between mildly affected horses and healthy horses. 298 
Proposed minimum database for both practitioners in the field and for research: The 23-point 299 
modified clinical score appears to best stratify horses with obstruction ranging from mild to severe. 300 
An application suitable for smart phone use would enhance the adoption of a common scoring tool.  301 
Lung function testing: In human asthma, the gold standard is the detection of variability in 302 
pulmonary function using spirometry or other methods of lung function testing.(38) Unfortunately, 303 
lung function testing remains available only to a few specialized centers, as more recently developed 304 
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portable lung function testing modalities are no longer on the market.(41) Initial reports from the 305 
author’s laboratory of a simple field test of respiratory resistance using the interrupter technique hold 306 
promise for increased use of lung function testing in the future. While the classic esophageal 307 
balloon/pneumotachometer method is effective in demonstrating increased maximal pleural pressure 308 
and allows for calculation of pulmonary resistance and elastance as well as dynamic compliance in 309 
severe EA, it is not sufficient for demonstrating abnormal function in mildly affected horses in which 310 
baseline lung function is rarely abnormal and histamine or other bronchoprovocation or 311 
bronchodilation must be used in order in order to detect low-grade obstruction.(56) Unfortunately, in 312 
some studies, even histamine bronchoprovocation has not been sufficient to distinguish between 313 
normal horses and horses with mild asthma,(52) and a lack of concordance between histamine 314 
bronchoprovocation and bronchoalveolar lavage (BAL) cytology has been noted in several 315 
studies.(57,58) While lung function testing and histamine bronchoprovocation have shown moderate 316 
to strong correlations with BAL cytology in some studies,(56,59,60) others have not.(57,58) Methods 317 
of performing histamine bronchoprovocation are equally important: studies in human asthmatics 318 
have shown that it is the total dose of histamine that is most important rather than the duration of 319 
exposure. A more precise method of dosing may be important to establish. In human athletes, indirect 320 
stimuli, such as cold air, hypertonic solutions such as mannitol, exercise, and AMP are all considered 321 
more accurate and useful in predicting asthma than are direct stimuli such as methacholine or 322 
histamine; this is an area that requires exploration in equine pulmonology. While hay challenge is 323 
useful for research in severe EA, it is inappropriate in a clinical case, especially in a horse that is 324 
expected to do athletic work.(3) In moderate to severe EA, variability in airflow should be 325 
demonstrated not through bronchoprovocation but through bronchodilation using either systemic 326 
(Buscopan™) or inhaled (albuterol, ipratropium bromide) drugs to assess reversibility; it is possible 327 
that a 24-hour period of bronchodilation is necessary for maximum effect in horses with 328 
diaphragmatic fatigue.(61) 329 
Proposed minimum database for both practitioners in the field and for research: In research, lung 330 
function should be assessed and airflow variability/changes in airway caliber should be assessed 331 
with either bronchoprovocation or bronchodilation. More research is necessary to determine if field 332 
assessment of lung function after bronchoprovocation or bronchodilation is sufficient to determine 333 
change with the 23-point scoring system. It is essential that a robust, easily used system for testing 334 
lung function in the field be developed.  335 
Airway secretions – bronchoalveolar lavage: Unlike in human pulmonology, examination of airway 336 
secretions is a primary method of diagnosis in EA, be it mild, moderate or severe. Although a 337 
standard volume of between 250-500 ml of saline using a 2-m long endoscope or 3-m BAL tube is 338 
recommended,(3) this practice is not always followed, and cytology should be assessed keeping in 339 
mind that the amount of fluid infused will affect the cell percentages. The relationship between BAL 340 
cytology and performance is still not clear. Certainly, poor performance has been associated with 341 
what have been determined to be abnormal cell types or percentages.(3) There has been much 342 
discussion as to what is normal on BAL cytology; it likely depends on a combination of technique, 343 
environment and population. Even the ‘stringent’ definition proposed by Couetil et al.(3) of <5% 344 
neutrophils, 2% mast cells, 1% eosinophils, would be considered elevated in some high-performance 345 
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populations.(62,63) Although an earlier study found no evidence of a clear phenotype in mast cell vs. 346 
neutrophilic inflammation with respect to pulmonary gas exchange during exercise,(64) recently, an 347 
increase in BAL mast cells or neutrophils was shown to negatively affect performance.(44) The way 348 
that cells are counted in BAL cytology is also important, especially for rare cells. In our laboratory 349 
we count a minimum of 500 cells at 400x for common cells such as macrophages and lymphocytes or 350 
neutrophils in mild EA, whereas for rare cells such as mast cells we count 1000 cells. Other 351 
techniques, such as using a 5-field differential for mast cells, are only useful if the cell density is 352 
high.(65) 353 
The conundrum of whether to assess airway fluid from both lungs rather than blind sampling, or to 354 
pool samples, has also occupied attention from researchers. One group found that, depending on 355 
whether the ‘loose’ or ‘stringent’ categorization was used, 8-37% of horses would have been 356 
categorized as control vs. mild-moderate EA if only one lung were used.(66) As it is the rare 357 
practitioner who has a bronchoscope in the field, it is unlikely that even pooled samples,(63) which 358 
may be a better representation of overall lung inflammation, will be taken other than in referral 359 
centers or practices. The problem is most important for rare cells. More attention will need to be paid 360 
in future to morphology and perhaps typing of cells. The existence of neutrophil extracellular traps 361 
(NETosis) in horses with severe EA presents an additional method to determine response to 362 
treatment(67), and recently the presence of degenerate neutrophils has been shown to raise suspicion 363 
for bacterial infection.(68) The question of macrophage morphology as an indicator of inflammation 364 
is also an area that will profit from further investigation.(69) Recently, as well, the paucigranulocytic 365 
phenotype has been described in which horses with clear signs of severe EA have low neutrophil 366 
percentages in the BAL.(46) This is thought to be due to mucus plugging of small airways that 367 
essentially sequesters neutrophils. Although a recent publication showed a rather shocking 81% of 368 
high-performing European horses with mild-moderate EA had fungal elements in the BAL,(62) this 369 
remains to be confirmed in other populations.  370 
Proposed minimum database for both practitioners in the field and for research: For the BAL, at 371 
least 250-mls of saline should be used, and there is a preference for counting at least 500 cells to 372 
adequately represent rarer cells. For research purposes where rare cells are of interest (e.g. mast 373 
cells or eosinophils), sampling of both lungs appears preferable. Better categorization of cells 374 
through morphological descriptions including apparent neutrophil extracellular traps and notations 375 
of fungal or birefringent elements should be done. Characterization of mucus on cytology may help 376 
to elucidate the paucigranulocytic phenotype. BAL in the field will usually be done blindly with a 377 
specialty tube.  378 
Airway secretions - tracheal wash (TW): The debate continues to swirl around the utility of tracheal 379 
wash vs. bronchoalveolar lavage, with Malikides et al.(70) finding a 37% disagreement in young 380 
racehorses, while Derksen et al.(71) determining that there was no correlation between BAL and TW, 381 
and others finding no relationship between tracheal neutrophil counts and racing performance;(72) 382 
thus, tracheal cytology has been considered inappropriate for diagnosis of mild EA.(3) Recently, 383 
however, a comparison of TW and BAL in 145 horses, along with evidence of mucus and endoscopy, 384 
found that only 17.5% of horses would have been classified differently if they had had the other 385 
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procedure, eventually concluding that there is no gold standard – except for mast cells, which are rare 386 
in the trachea, and thus, to be found, demand that a BAL be performed.(73)  387 
Proposed minimum database for both practitioners in the field and for research: Tracheal wash may 388 
be most practical for some practitioners in the field and has the added benefit of allowing for 389 
bacterial culture. The inability to assess mast cells adequately continues to limit this modality. In 390 
research settings, both tracheal aspirate and BAL are preferable.  391 
Endoscopy: Many clinical diagnoses are made on the basis of endoscopic visualization of mucus, 392 
with strong support from the finding that tracheal mucus quite nicely correlated with racing 393 
performance or lack thereof.(72) The recent consensus statement considers that the demonstration 394 
through tracheobronchial endoscopy of mucus grade 2/5 in racehorses or 3/5 for sport/pleasure 395 
horses is sufficient to diagnose mild-moderate EA and in support of this recommendation, Rossi et 396 
al.(73) found that visible mucus in the trachea is indeed likely to predict inflammation. There are 397 
varying degrees of certainty about mucus in the trachea predicting inflammation.(49,62,74,75) 398 
Nonetheless, other studies have shown that mucus is insufficient to parse out mild vs. unaffected 399 
cases.(76) Endoscopy has also been shown to be useful in detecting an increase in upper airway 400 
abnormalities in horses with mild-moderate EA, with Courouce-Malblanc et al.(77) raising the 401 
chicken-and-egg question of the relationship between mild-moderate EA and dorsal displacement of 402 
the soft palate, and more recently, Wysocka et al.(78) found that more horses with mild-moderate EA 403 
had dynamic pharyngeal abnormalities. It may be that the answer will rest in whether any of these 404 
modalities can help to define a phenotype rather than simply further describing an already understood 405 
phenotype. 406 
Proposed minimum database for both practitioners in the field and for research: Upper airway 407 
endoscopy should be performed to rule out upper airway cause of obstruction as a primary cause of 408 
signs or that might confound lung function testing. Assessment of tracheal mucus should be 409 
performed. 410 
Bronchial biopsies/brushings: Endobronchial biopsies offer an excellent method of sampling larger 411 
airways, although deeper layers cannot be accessed. The brass ring – being able to distinguish normal 412 
from remission or mild EA – remains elusive, however, as correlates were evident between 413 
histopathology and impulse oscillometry and showed a difference between horses in remission at 414 
pasture and those that remained stabled and treated with glucocorticoids, but did not show any 415 
difference between horses with severe EA in remission and controls.(79) 416 
Proposed minimum database for both practitioners in the field and for research: At this time, 417 
brushings/biopsies are not considered part of a minimum database 418 
Radiography/ultrasound: Imaging is considered an important ancillary diagnostic in humans, but 419 
radiographs have not been shown to be sensitive or specific in horses with EA.(80) Chest CT is 420 
currently not feasible in large animals. While endobronchial ultrasound shows promise for the 421 
elucidation of airway smooth muscle thickening in severe EA, the ultimate goal of being able to 422 
detect low-grade disease in erstwhile healthy horses, or to distinguish normal from severe EA in 423 
remission remains elusive.(79) 424 
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Proposed minimum database for both practitioners in the field and for research: at this time, 425 
imaging is not considered part of the minimum database. 426 
 427 
Health effects of equine asthma – Laurent Couetil 428 
Equine asthma encompasses mild to severe forms of chronic airway inflammation. Severe EA affects 429 
approximately 14-17% of horses in countries with Northern, cool climate.(47,81) Mild-moderate EA 430 
affects 68-77 % of pleasure horses based on tracheal wash cytology (neutrophils > 20%) and up to 431 
80% of racehorses based on BAL cytology.(44,75) 432 
Severe equine asthma: 433 
Horses affected with severe EA experience exacerbation of clinical signs when exposed to organic 434 
dust originating from hay and bedding, in particular molds present in poor quality hay. As a result, 435 
clinical signs tend to be worse during the winter when horses are housed indoors for extended periods 436 
of time.(82) Some horses exhibit disease flare-ups while at pasture during summer months 437 
(EPA).(25) These horses improve clinically during winter or after being housed indoor. A small 438 
percentage of horses appear to suffer from both classic severe EA and EPA. Horses with severe 439 
asthma tend to be mature (>7 years) to old animals and a genetic predisposition has been identified in 440 
some families.(83,84)  441 
The main clinical sign characteristic of severe EA is increased respiratory effort (“dyspnea”) that can 442 
rapidly improve following bronchodilator administration. Although the decrease in respiratory effort 443 
following bronchodilator administration can be detected within minutes of drug administration using 444 
lung function testing, clinical improvement may not be apparent to clinicians.(85) Acute exacerbation 445 
is associated with increased pulmonary artery and right-heart vascular pressures as well as increased 446 
pulmonary artery diameter on ultrasound.(86) Blood pressure return to baseline during clinical 447 
remission however, cardiac ultrasound abnormalities such as right ventricular wall thickness 448 
remained increased.(86) Surprisingly, severe EA is rarely fatal unless complications develop such as 449 
cor pulmonale.(87) Affected horses are more likely to be euthanized because owners get discouraged 450 
with the expense associated with chronic therapy and maintaining a low-dust environment.(83) 451 
Coughing and nasal discharge are non-specific signs of respiratory disease commonly reported in 452 
horse with severe EA.(47) Horses with a history of both coughing and mucoid nasal discharge are at 453 
increased risk of developing severe EA.(88) Thoracic auscultation may reveal increased breath 454 
sounds bilaterally, extended area of auscultation, and abnormal breath sounds (i.e. crackles, 455 
wheezes). However, the thick chest wall of horses makes auscultation an insensitive indicator of 456 
pulmonary disease, with abnormal findings obtained in less than 50% of horses with severe EA.(88)1 457 
 458 
 459 
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Strict management changes or medical therapy will results in rapid improvement in clinical signs 460 
however, if exposure to triggering factors is not addressed improvement will be short lived or 461 
incomplete.(3,15) 462 
Mild/moderate equine asthma: 463 
This form of mild respiratory disease is mainly subclinical with horses showing non-specific signs 464 
such as intermittent coughing and poor performance.(3) However, mild asthma should not be ruled 465 
out in horses that do not cough because coughing is reported in only 38% of horses with mild 466 
asthma.(89) Coughing is associated with increased BAL neutrophils.(56) 467 
Poor performance and reduced willingness to perform are associated with increased tracheal mucus 468 
scores in racehorses and show-horses, respectively.(72,90) In racehorses, poor performance has been 469 
associated with increased neutrophils and mast cells in BAL fluid.(44)  470 
There is an association between nasal discharge and increased tracheal mucus in racehorses.(49) 471 
However, the association between tracheal mucus and BAL cytology has not been reported yet. 472 
 473 
Tissue remodeling in equine asthma and functional consequences - Michela Bullone 474 
The term “remodeling” defines a process resulting in a tissue that is structurally and architecturally 475 
altered compared to its healthy counterpart. In asthma, structural alterations are represented by 476 
quantitative or qualitative changes of the bronchial wall components or their surrounding tissues, 477 
whilst architectural alterations refer to the skewed relationships among such structures.  478 
Airway remodeling has been studied only in horses affected by severe EA. An increased expression 479 
of metalloproteinases and their tissue inhibitors has been recently reported in a group of horses with 480 
mild respiratory signs and BAL cytology compatible with mild EA.(91) However, the possibility that 481 
the horses studied were horses with severe EA in remission of the disease was not excluded. 482 
Almost all airway components undergo remodeling in severe EA, both in peripheral (diameter < 2 483 
mm) and central airways. The airway smooth muscle mass as well as collagen and elastic fiber 484 
deposition are increased in the lamina propria of peripheral airways during severe EA remission 485 
compared to healthy airways.(92,93) Mucostasis, mucus cell hyperplasia, peribronchiolar metaplasia, 486 
and interstitial fibrosis are more frequently detected in horses with severe EA in remission compared 487 
to controls.(94) However, histomorphometric techniques revealed no differences in the number of 488 
mucus cells per mm of lamina reticularis or in the volume of stored mucosubstance in bronchial 489 
epithelial cells.(95) Central airway remodeling during disease remission is less pronounced compared 490 
to what is observed peripherally. Whether airway submucosal structures are significantly altered 491 
during severe EA remission compared to control remain to be established.(79,96,97)  492 
Functionally, severe EA remission is associated with a normal lung function in spite of significant 493 
structural alterations of the airways. In these conditions, the respiratory resistance correlates with the 494 
amount of collagen within the lamina propria of peripheral airways,(93) indicating that, in the 495 
  Equine asthma 
 
14 
absence of bronchospasm, peripheral airway stiffness is the major determinant of respiratory 496 
resistance in asthmatic horses. The functional implications of peripheral remodeling become more 497 
important during disease exacerbations, when most of the changes are further accentuated and the 498 
mechanics of breathing are altered.(73,94)  499 
There is no doubt that the major determinant of airway obstruction during severe EA exacerbations is 500 
smooth muscle contraction and that central airways play a major role.(98) By definition, the force 501 
produced by a muscle is proportional to its cross-sectional area. Given the increased smooth muscle 502 
mass (and cross-sectional area) during severe EA exacerbations,(79) asthmatic muscle is “stronger” 503 
and able to contract the thickened lamina propria observed in severe EA, further reducing the airway 504 
lumen. Increased mucus secretions into the airway lumen also contribute to airway occlusion.(99) 505 
These same mechanisms operate in peripheral airways, where the effects on lung function are 506 
somewhat blunted by the fact that their overall contribution to pulmonary resistance is low, due to 507 
their large cumulative cross-sectional area.(100) At this level, the more relevant functional effects of 508 
remodeling are the loss of lung elasticity and airway-parenchymal tethering. Adequate small airway 509 
patency is guaranteed by their intimal connection to the lung parenchyma by elastic and connective 510 
fibers. When the lung inflates during inspiration, small airways are stretched and passively dilate. 511 
Remodeling of elastic fibers and of the extracellular matrix within and around the airways and in the 512 
alveolar septa alters this mechanism, preventing the smallest airways from remaining open.(101) The 513 
effect is even worse during expiration, when the lungs physiologically recoil and the airway diameter 514 
physiologically narrows. With a significantly impaired expiratory airflow, part of the air that reaches 515 
the alveoli remains trapped. This leads horses with severe EA in exacerbation to breath at increasing 516 
lung volumes (functional residual capacity(102)) in the attempt to maintain airway patency, which 517 
causes lung hyperinflation and enlarged fields of thoracic auscultation.(103)  518 
 519 
British racing veterinarians’ views and practices relating to mild-moderate equine asthma –520 
Tierney Kinnison & Jacqueline M Cardwell 521 
Anecdotal evidence to date has suggested that, although BAL sampling is widely accepted elsewhere 522 
as the diagnostic tool of choice for cytological assessment of equine lower airways, tracheal endoscopy 523 
and tracheal wash-based diagnostics have remained the mainstay of routine clinical lower airway 524 
investigations in British Thoroughbred racehorses in training. Given the emphasis on BAL in research, 525 
this would present a considerable challenge to furthering evidence-based respiratory medicine in this 526 
important equine population. In a recent study we investigated British racing veterinarians’ rationales 527 
for current practices, and the challenges they face in relation to diagnosing and managing racehorse 528 
airway inflammation.(104) 529 
Qualitative data were gathered through semi-structured focus group discussions designed to capture 530 
current practices and opinions relating to the diagnosis and treatment of lower airway inflammation, 531 
as well as familiarity with and views on the most recent ACVIM consensus statement,(3) in which the 532 
term ‘mild-moderate equine asthma’ was recommended. Four British veterinary practices, two 533 
primarily serving the flat racing community and two primarily serving the National Hunt (jump racing) 534 
community, in different geographical regions of England, were purposively selected to participate. 535 
Focus group discussions were conducted at the practice premises, moderated by one of the authors 536 
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(TK), an experienced qualitative researcher who is not a veterinarian. Discussions were audio-recorded 537 
and transcribed verbatim, and transcripts were analyzed using an inductive, thematic analysis.  538 
In total, 25 participants contributed to the focus group discussions (number per group ranged from 3 539 
to11). All were veterinarians (experience ranging from recent graduate to senior partner), with the 540 
exception of one laboratory team member and one veterinary student, and five were women. 541 
Discussions lasted between 46 and 74 minutes.  542 
Three key themes were developed through analysis of focus group data: (i) An over-arching theme of 543 
serving the racing industry within which two further themes (ii) disregarding of the consensus and (iii) 544 
the pragmatic clinician were nested. 545 
(i) Serving the racing industry: This was a key driver of clinical approaches to racehorse respiratory 546 
health, which were strongly trainer-influenced in particular. The trainer selects horses for endoscopic 547 
respiratory assessment, often because of training and racing schedules rather than any clinical signs, 548 
and the approach to investigation and treatment is strongly influenced by trainer expectations. This 549 
varies with trainer personality, experience and training methods, as well as stage of the racing season, 550 
signalment of the affected animal and general health on the yard, and is in turn driven by commercial 551 
pressures of the racing industry.  552 
(ii) Disregard of the consensus: The unanimous view across all four groups was that the condition 553 
defined as mild-moderate EA by current concensus(3) is largely not seen in British racehorses which, 554 
in the participants’ considerable collective experience, are affected predominantly with excess 555 
endoscopically-visible tracheal mucus largely attributed to bacterial infections. It was also considered 556 
unfeasible to fulfil two key aspects of the consensus case definition: waiting for chronicity of clinical 557 
signs (>3 weeks duration), and performing BAL sampling. Neither of these would be acceptable to 558 
trainers, according to participants, and participants themselves were not convinced of the extra value 559 
of BAL sampling. The consensus statement was therefore seen as having been developed for outsiders, 560 
by outsiders without sufficient understanding of culture and practices on British racing yards. 561 
(iii) The pragmatic clinician: Participants shared a strong professional identity as pragmatic clinicians 562 
often required to base clinical decision-making on direct personal or collective experience, rather than 563 
on research-based or laboratory evidence. Cytological examinations of tracheal wash samples were 564 
defended as valuable when interpreted sequentially and combined with knowledge of the history and 565 
idiosyncracies of the individual horse and yard. Although this approach was generally viewed 566 
positively as flexible and individualized, participants did also express some frustration with the 567 
sometimes unsatisfactory jigsaw of diagnostic information available to them, particularly in relation to 568 
discrepancies between clinical and laboratory findings. 569 
Our work has highlighted a lack of alignment between clinical practice on British racing yards and 570 
international consensus on diagnosing lower airway inflammation, which constitutes a barrier to 571 
furthering development of a contextually-relevant evidence-base for this population. Equine clinicians 572 
elsewhere may find themselves in disagreement with some of the opinions expressed, or practices 573 
described, by our study participants. However, these investigations were designed to understand the 574 
experiences and rationales of clinicians in the specific context of British racing practice. The strength 575 
and consistency of views expressed support the anecdotal evidence that, in this context, tracheal 576 
endoscopy and wash sampling are widely regarded as the best available means of providing the non-577 
invasive monitoring of respiratory health expected by trainers and used to inform training- and racing-578 
related decisions. It would be interesting to determine whether similar approaches are being taken 579 
elsewhere, particularly in populations of yearling and two-year old Thoroughbred racehorses in 580 
training. Given the considerable resistance to BAL sampling in British racing, development of new 581 
tracheal-based or other minimally-invasive diagnostics, including appropriate biomarkers and suitably 582 
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sensitive, portable lung function tests, would be valuable. Furthermore, our participants’ views that 583 
mild-moderate EA as defined by current consensus is largely not seen in British racehorses suggest 584 
that research furthering our understanding of the etiology and pathogenesis of airway inflammation in 585 
this equine population is still required. 586 
 587 
The microbiome in equine asthma – Renaud Leguillette 588 
The respiratory system is an interface between the outer environment and the inner body. Lower 589 
airways have historically been seen as a sterile milieu, thanks to the anatomical configuration, local 590 
surface immunity and mucus production and clearance systems.(105) However, with the 591 
development of high sensitivity and high throughput technologies, the microbiota of the respiratory 592 
system has been described in healthy subjects in many species, including horses.(106,107) Further 593 
investigation of the relationship between infectious agents, lower respiratory tract microbiota and the 594 
development of mild EA is warranted. We and others have reported descriptive results about the 595 
microbiota of horses with mild EA,(107,108) but the causality between bacterial flora and the disease 596 
is far from being understood.  597 
Studies on the microbiome use DNA extraction followed by high throughput amplification and 598 
sequencing of the 16S amplicon.(109) The sequences are then filtered and aligned against a 599 
taxonomy database to identify and organize operational taxonomic units (OTUs). Descriptive 600 
analysis of the phyla, OTUs and bacterial species are then performed, followed by statistical analysis 601 
at the community level (within and between samples; alpha and beta diversity respectively) and at the 602 
individual level (OTU diversity analysis). Statistical analysis can be used to compare between 603 
groups: healthy horses versus those with mild asthma, upper versus lower respiratory tract.(109) 604 
The lower airways have a decreased richness (alpha diversity, corresponding to the number and 605 
proportion of each bacterial species) when compared to the upper airways in healthy horses.(107) 606 
However, a very large majority of the same OTUs are present in both the upper and the lower 607 
airways, showing an overlap and some continuity in the bacterial population between the two 608 
anatomical environments in healthy horses. Furthermore, treatment with corticosteroids did not affect 609 
the composition of the bacterial flora in the upper airways.(107) The role of the upper airways 610 
microbiota in mild EA is unknown, but two studies did not find any difference in beta diversity of the 611 
upper airways between healthy horses and those with mild EA.(107,108)  612 
The relationship between bacteria and the lower respiratory tract of the equine host seems to be 613 
dynamic. As an example, a change in the environmental respirable particulates has an effect on the 614 
lower respiratory tract flora in horses. Furthermore, treatment with systemic or nebulized 615 
dexamethasone induces some changes in the microbiota of the lower respiratory tract in both healthy 616 
and mild asthma horses.(107) Systemic dexamethasone administration decreased the evenness of the 617 
flora and increased the abundance of 9 OTUs. There is an agreement between studies that the lower 618 
airways microbiota between healthy and mild EA horses are clearly different.(107,108) Interestingly, 619 
Streptococcus is one of the 6 OTUs which differed with disease status, and was the OTU with the 620 
greatest increase in relative abundance in mild EA.  621 
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The effect of the environment on the composition of the lower airways’ microbiota is also a common 622 
finding between studies.(107,108) However, a study found that treatment with corticosteroids had 623 
more effect on the composition of the bacterial flora than changes in the environment.(107) 624 
The microbiome studies are recent in equine medicine and are limited to being descriptive. The 625 
challenge for the scientific community will be to answer the causality dilemma of the chicken or the 626 
egg regarding the role of the airway microbiota in mild EA. 627 
 628 
Role of viruses in equine asthma – Nicola Pusterla 629 
Human asthma 630 
Asthma development in humans is most probably caused by the interaction of multiple factors, 631 
including genetics, allergen exposure, microbiome and invading pathogens. Human rhinovirus, 632 
human respiratory syncytial virus, human metapneumovirus, human parainfluenza virus, human 633 
enterovirus and human coronavirus are strongly associated with asthma exacerbations.(110) The 634 
association between human rhinovirus-induced wheezing and the development of childhood 635 
asthma/wheezing has been confirmed in a recent meta-analysis.(111) The risk for asthma by age 6 636 
years has been shown to increase (odds ratio 9.8) if children have been wheezing with rhinovirus 637 
during the first 3 years of life.(112) Further, many prospective long-term follow-up studies have 638 
shown that human respiratory syncytial virus-induced bronchiolitis is associated with later 639 
development of asthma.(113) However, the pathogenic role of respiratory viruses as triggers for the 640 
development and/or exacerbation in asthmatic human patients has not been fully characterized. 641 
Changes in the immune response to viral infections in genetically predisposed individuals are very 642 
likely to be the main factor involved in the association between viral infection and asthma.(114) 643 
 644 
Equine asthma 645 
The pathogenesis of EA remains incompletely defined. However, similar to human asthma, a 646 
multifactorial process is suspected. Conditions associated with exercise, feeding and housing 647 
practices, location, seasonality, infection of the upper and lower airways and genetic influences have 648 
been linked to EA (7,8).(115,116) A variety of viral (equine influenza virus (EIV), equine 649 
herpesviruses (EHV) equine rhinitis viruses (ERVs)) and bacterial (Streptococcus equi subspecies 650 
zooepidemicus, Actinobacillus spp., Pasteurella spp.) etiological agents have been linked to mild to 651 
moderate EA.(49,117) It remains to be determined if these agents are triggers for the development of 652 
EA or are secondary colonizers of already compromised airways. 653 
 654 
Evidence for viruses in equine asthma  655 
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Viral respiratory infections are one of the most common health problems in horses throughout the 656 
world (Table 1). These infections are often self-limiting and a full recovery can be expected in most 657 
horses. Young performance horses, such as racing horses, have an increased risk of respiratory viral 658 
infections. This relates to age susceptibility, commingling, stress and suboptimal biosecurity 659 
protocols.(118–120)  660 
Amongst respiratory viruses, only EIV and ERVs have an affinity to the lower respiratory tract, 661 
leading to airway hyperresponsiveness. Clinical signs associated with EIV are usually more severe 662 
than those seen with mild to moderate EA. Further, no association has been determined between mild 663 
to moderate EA and infections with EIV, EHV-1 and EHV-4.(121–123) This is in sharp contrast to 664 
the detection of ERVs (ERAV and ERBV), known to cause subclinical or mild clinical disease.(121–665 
123) In a recent study, horses with mild to moderate EA were significantly more likely to have a 666 
positive titer as well as higher log-transformed titers to ERAV when compared to control 667 
horses.(121) In another study, the detection of ERBV by qPCR was significantly associated with 668 
coughing in Standardbred racehorses in training.(122) Subclinical respiratory viral activity in horses 669 
with poor performance has been associated with EHV-2 and EHV-5 infection.(121,122) In a recent 670 
study, the detection of EHV-2 by qPCR in nasal secretions was significantly associated with mild to 671 
moderate EA.(121) In another study, the detection of EHV-2 by qPCR was significantly associated 672 
with coughing and excessive tracheal mucus in Standardbred racing horses.(122) These results are in 673 
sharp contrast to two recent studies performed on 66 Swedish Standardbred trotters, which were 674 
followed for 13 months via qPCR analysis of nasal secretions and serology.(123,124) Despite 675 
occurrence of poor performance and subclinical viral activity in the Swedish Standardbred trotters, 676 
the authors were unable to detect associations between EHV-2/-5 and clinical respiratory disease 677 
and/or poor performance. These conflicting results reflect the ongoing challenges in establishing 678 
causality between mild to moderate EA and gamma herpesviruses, known to be ubiquitous in both 679 
healthy and clinically affected horses.  680 
In conclusion, associations between specific viruses detected via antigen or antibody detection and 681 
clinical signs of mild to moderate EA may suggest that viruses may play a role in triggering or 682 
exacerbating asthma. However, because some viruses are ubiquitous both in healthy and clinically 683 
affected horses or are often associated with subclinical disease, establishing causality is challenging 684 
and in need for further research. 685 
 686 
TABLE 1. Association of respiratory viruses with mild to moderate equine asthma based on antigen 687 
and/or antibody detection.  688 
Virus Year Country  Population  Sample 
type 
Outcome Ref. 
EAV 2015 Sweden STBD trotters NS No detection by qPCR 122 
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2015 
2015 
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2015 
2015 
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2015 
2015 
2016 
2016 
2016 
2016 
Sweden 
USA 
France 
Sweden 
USA 
France 
 
Sweden 
USA 
France 
 
Sweden 
USA 
French 
 
Sweden 
USA 
France 
 
 
Sweden 
USA 
France 
France 
France 
France 
STBD trotters 
Adult horses  
STBD trotters  
STBD trotters 
Adult horses 
STBD trotters 
 
STBD trotters 
Adult horses 
STBD trotters 
 
STBD trotters 
Adult horses 
STBD trotters 
 
STBD trotters 
Adult horses 
STBD trotters 
 
 
STBD trotters 
Adult horses 
STBD trotters 
STBD trotters 
STBD trotters 
STBD trotters 
NS 
BAL fluid 
NS, TW 
NS 
BAL fluid 
NS, TW 
 
NS 
BAL fluid 
NS,  
TW 
NS 
BAL fluid 
NS, TW 
 
NS 
NS 
NS,  
TW 
 
NS 
BAL fluid 
NS, TW 
NS, TW 
NS, TW 
NS, TW 
No detection by qPCR 
No detection by qPCR 
No detection by qPCR 
No association with PP 
High seroprevalence and titers 
No detection by qPCR 
No association with equine asthma 
No association with PP 
No association with equine asthma 
No association with equine asthma 
Detection by qPCR in horses with cough  
No association with PP 
No detection by qPCR 
No association with equine asthma 
 
No association with PP 
Detection associated with equine asthma 
No association with equine asthma 
Detection by qPCR in horses with cough 
and excessive tracheal mucus 
No association with PP 
No association with equine asthma 
No association with equine asthma 
No detection by qPCR 
No association with equine asthma 
No detection by qPCR 
122 
120 
121 
122 
120 
121 
 
122 
120 
121 
 
122 
120 
121 
 
123 
120 
121 
 
 
123 
120 
121 
121 
121 
121 
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BAL: bronchoalveolar lavage; EAV: equine arteritis virus; EAdV: equine adenovirus; NS: nasal 689 
secretions; PP: poor performance; STBD: Standardbred; TW: tracheal wash 690 
 691 
Role of Non-infectious Exposures in Equine Asthma – Katy Ivester 692 
A growing body of research demonstrates the link between organic dust exposure and EA. 693 
Introduction of horses to high dust environments not only induces profound BAL fluid neutrophilia 694 
and airway obstruction in horses susceptible to severe asthma, but also significant neutrophilic 695 
airway inflammation in previously healthy horses.(125,126) Outside of the experimental exposure 696 
setting, higher dust exposure has also been associated with increased risk of tracheal mucus 697 
accumulation in racing Thoroughbreds.(127) 698 
 699 
Barn dust is a complex mixture, rich in potential sources of allergens as well as immunomodulators 700 
such as endotoxin and β-glucan.(128,129) In addition to individual horse factors such as age and 701 
susceptibility, this complexity may partially account for the heterogeneity of asthma phenotypes. 702 
Respirable particulates, nominally less than 4 μm in diameter, have been linked to eosinophilic 703 
inflammation in young Thoroughbreds entering race training(130) and neutrophilic inflammation in 704 
actively racing Thoroughbreds.(44) Increasing respirable endotoxin exposures have been shown to 705 
provide an apparent protective effect against neutrophilic inflammation at low doses,(44) while high 706 
doses of endotoxin augment the inflammatory response to particulates,(131) suggesting a non-linear 707 
response to inhaled endotoxin in the horse. Mast cell inflammation has been found to be common in 708 
both young, untrained Thoroughbreds(130) and those that are actively racing,(44) but unrelated to 709 
respirable dust or respirable endotoxin exposures. Instead, BAL mast cell proportions are related with 710 
respirable β-glucan exposures. Conversely, inhalable dust exposures have not been found to affect 711 
BAL inflammatory cell proportions. Thus, inhalable particulates, those nominally less than 100 μm 712 
in diameter, appear to be less relevant than respirable particulates in equine respiratory health. 713 
 714 
Setting exposure recommendations will require better understanding of the dose-response to inhaled 715 
non-infectious agents across wider ranges of age, breed, and discipline through study designs that 716 
include both exposure and respiratory health outcome measures and utilize appropriate statistical 717 
tools to relate them. Advanced characterization of respiratory health, such as investigation of alveolar 718 
macrophage function and BAL fluid cytokine profiles, coupled with extensive exposure assessment 719 
is likely to offer valuable insight into EA pathophysiology and identify new targets for intervention. 720 
Miniaturization of optical particle counters has rendered real-time breathing zone exposure 721 
measurements on the horse both affordable and technically feasible. Finally, the equine airway is 722 
arguably most susceptible to particle penetration during athletic exertion due to large tidal volumes 723 
and extension of the head and neck, yet the exposures that horses sustain during exercise are largely 724 
unexplored. Such measures of exposure are complicated by the air speed and turbulence generated at 725 
the breathing zone during such activity and will require specialized sampling strategies. 726 
  Running Title 
 
21 
 727 
The role of neutrophils in equine asthma – Gabriel Moran 728 
Neutrophils are key actors in host defense, migrating toward sites of inflammation and infection, 729 
where they act as early responder cells toward external insults.(132) However, neutrophils can also 730 
mediate tissue damage in various non-infectious inflammatory processes. Airway inflammation is 731 
one of the primary characteristics of an asthma-affected horse’s response to aeroallergens with 732 
neutrophilic bronchiolitis being the main lesion.(133) The mechanism by which airway inflammation 733 
develops in EA is a multifaceted and dynamic process. Current knowledge suggests that the 734 
inflammatory component of this disease results from a combination of both the innate and adaptive 735 
immune responses.(134) Generally, airway inflammation involves activation of pathogen-specific 736 
inflammatory cells, modulation of gene transcription factors, and release of inflammatory 737 
mediators.(135) Within the airways, neutrophils likely contribute to bronchoconstriction, mucus 738 
hypersecretion, and pulmonary remodeling by release of pro-inflammatory mediators, including the 739 
cytokines interleukins 8 and 17, neutrophil elastase, reactive oxygen species, and neutrophil 740 
extracellular traps (NETs).120–123 Oxidative stress in horses with asthma is evidenced by the increase 741 
in elastase and decrease in ascorbic acid concentrations in BALF associated with neutrophilia 742 
secondary to exposure to organic dust.(136) The pathogenic role of NETs has been described for 743 
many infectious and non-infectious human diseases, including respiratory cases with a massive influx 744 
of neutrophils into the airways.(137) Excessive NET release is particularly deleterious in lung 745 
diseases because NETs can expand easily in the pulmonary alveolar space and cause lung injury. 746 
Furthermore, NETs and their associated molecules can directly induce epithelial and endothelial cell 747 
death.(138)  748 
The mechanisms that regulate neutrophil functions in tissues are complex and incompletely 749 
understood and must be regulated with exquisite precision and timing. Timely apoptosis of 750 
neutrophils is central to the resolution of inflammation; dying neutrophils are known to stimulate 751 
their own efferocytosis, inducing macrophagic transition from a pro-inflammatory to an anti-752 
inflammatory profile.(139) Thus, dysregulated apoptosis and mechanisms of inflammation may play 753 
an important role in the pathogenesis of EA. The persistence of apoptosis-resistant neutrophils in the 754 
airways of horses with asthma may also impede timely neutrophil clearance and delay the resolution 755 
of airway inflammation. The discovery and development of compounds that can help regulate ROS, 756 
NET formation, cytokine release and clearance of airway neutrophils would be highly beneficial in 757 
the design of therapies for EA.(133) 758 
 759 
Insights into equine asthma pathophysiology from transcriptomics – Dorothee Bienzle 760 
Asthma is a highly heterogeneous condition of the lung. Akin to the lining of the gastrointestinal 761 
tract, the lining of the airways is also in contact with external substances throughout life. Ingested 762 
substances generally pass through the gastrointestinal tract unidirectionally, and a careful balance 763 
between processing of digested food materials, nutrient absorption and limiting immunoreactivity is 764 
maintained during homeostasis, with well-known severe consequences of deviations in this balance. 765 
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The airways function differently in that only gaseous substances normally pass into the distal alveoli 766 
and are exhaled in the reverse direction. Inhaled particulates also have to be expelled in reverse 767 
direction toward the nasopharynx by largely mechanical means or taken up by alveolar macrophages 768 
for disposition with minimal inflammatory evocation.(140) Hence, a complex and selective epithelial 769 
barrier with differing functions characterizes both organs. 770 
 771 
The epithelium lining the airways has unique composition, morphology and function throughout the 772 
lung, and is intimately connected to subepithelial structures such as the basement membrane, mucous 773 
glands, smooth muscle, fibroblasts, endothelium and immune cells. The epithelium forms a barrier 774 
between inhaled components and the subepithelial constituents, and also has to balance efficient 775 
transfer of gases with controlled reactivity to non-gaseous components. While the lesions of severe 776 
EA manifest predominantly with inflammation, smooth muscle hyperplasia and fibrosis of the 777 
peripheral airways and surrounding tissues, the larger airways are exposed to the same inhaled 778 
substances and also have morphological, functional and molecular changes.(141)  779 
 780 
Research initially focused on the role of club cell secretory protein (CCSP), a member of the 781 
secretoglobin family produced by non-ciliated epithelial cells concentrated within the epithelium at 782 
the transition from bronchi to bronchioles. Club cells are recognized as epithelial progenitor cells that 783 
can differentiate into ciliated and other specialized cells of the airway epithelium, participate in 784 
reduction of reactive oxygen toxicants through cytochrome enzymes, and their hydrophobic secreted 785 
protein inactivates a range of inflammatory mediators. Horses with severe asthma have fewer club 786 
cells and lower concentration of CCSP in airway fluids, which may be a function of chronic 787 
inflammation resulting in reduced regenerative capacity of the airway epithelium.(142) Unique 788 
relative to other mammals, equids have two expressed CCSP genes that differ in 12 of 70 amino 789 
acids, and also in their interaction with hydrophobic molecules.(143) Recombinant eCCSP increased 790 
neutrophil oxidative burst, phagocytosis and extracellular trap formation, lending support to the 791 
notion that loss of club cells has deleterious effects on lung health.(144) 792 
 793 
Whole transcriptomic changes in endobronchial epithelial biopsies from sites from 5th to 12th 794 
generation bronchi were investigated with next-generation sequencing. Each horse served as its own 795 
control to identify changes in gene expression associated with an inhaled challenge since inter-796 
individual variability exceeded changes attributable to the challenge. A bioinformatics pipeline 797 
including quality control measures to account for duplicates, variable sequencing depth and 798 
dispersion was implemented, results were mapped to the equine genome, and predicted proteins were 799 
procured with a combination of software and manual approaches to assign appropriate Ensemble IDs 800 
for analyzing interactions. An overall conservative analytic approach yielded 111 genes differentially 801 
expressed in horses with severe asthma as a result of a challenge, with the majority up-802 
regulated.(145) Not surprisingly, many up-regulated genes pertained to inflammatory mediators and 803 
effectors and were well known members of protein interacting networks. However somewhat more 804 
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surprisingly, genes with altered expression also concerned more broadly epithelial cell formation and 805 
maintenance, and the circadian rhythm, suggesting that multiple cell properties are affected in 806 
exacerbated EA at the transcriptomic level. Subsequent analysis of enriched gene sets in asthmatic 807 
horses further highlighted the importance of cell cycle regulation and repair pathways.(146) 808 
 809 
Transcriptomic studies of this nature yield a great deal of information, which requires subsequent 810 
confirmation regarding cell specificity, correlation with protein expression and function, and 811 
extension to a more robust number of affected and unaffected individuals. Albeit, there is strong 812 
evidence to indicate that the bronchial epithelium is profoundly altered during exacerbation of severe 813 
EA, and this insight offers new venues for investigating the role of specific proteins and for potential 814 
therapeutic targets.(147,148) 815 
 816 
Genetic risk factors of equine asthma – Vince Gerber 817 
The entire spectrum of EA is influenced by interactions between the environment and genetics, but 818 
almost all research in this field has focused on the severe clinical phenotype.  819 
While no specific genetic risk factors have been reported for mild to moderate forms of EA, genetic 820 
susceptibility to certain bacterial lower airway infections could potentially be relevant.(149) 821 
Furthermore, mild but persistent respiratory signs such as occasional coughing and nasal discharge 822 
may represent early phenotypic indicators for an increased risk to later development of severe 823 
EA.(88) This suggests that the genetics of milder forms of EA may be worth investigating in 824 
longitudinal studies.  825 
Severe EA has been shown to be partly heritable in several breeds and has been the focus of genetic 826 
research involving family and epidemiological studies, whole-genome scans and investigation of 827 
candidate genes. Reports of marked familial aggregation of severe EA date back 70 years.(150) 828 
Parent, age, and stable environment have significant additive effects that increase the risk for 829 
developing severe EA as defined by a history of persistent frequent coughing and/or increased 830 
breathing effort.(43,151) Offspring of affected sires have a more than four-fold increased risk for 831 
developing severe EA.(50) 832 
Whole genome scans in high-prevalence families indicate two chromosome regions with a genome-833 
wide significant association with severe EA.(152) Importantly, the associations differ between the 834 
families: region ECA13 in one family and ECA15 in another family. Further association and gene 835 
expression studies indicate interleukin 4 receptor as a candidate gene in a subset of EA-affected 836 
horses. Molecular pathway analyses of genomic and proteomic data showed interactions between 837 
interleukin 4 receptor and SOCS5 upstream of an important molecular cascade involving nuclear 838 
factor κB.(153)  839 
So far, no causal genetic variant has been identified in interleukin 4. An allelic case-control genome-840 
wide association study in the general Warmblood population revealed another region on chromosome 841 
  Equine asthma 
 
24 
13. The best-associated marker was located in the protein-coding gene TXNDC11, which may be 842 
involved in regulating hydrogen peroxide production in the respiratory tract epithelium as well as in 843 
the expression of MUC5AC mucin.(154) No genomic copy number variations were found to be 844 
associated with severe EA.(155) Integrative analyses combining GWAS, differential expression 845 
(DE), and expression quantitative trait loci (eQTLs) were not able to uncover causative genetic 846 
variants that contribute to severe EA through gene expression regulation. However, results showed 847 
interesting similarities to human asthma with disease-associated genetic variants in CLEC16A that 848 
also regulate gene expression of DEXI.(156) Furthermore, global gene expression studies of mRNA 849 
and miRNA levels in these high-prevalence families have shown impaired cell cycle regulation and 850 
CD4⁺ T cell differentiation into Th2/Th17 cells, respectively, in severe EA.(157,158) 851 
At present, none of these associations are useful genetic markers in the general population. Most of 852 
the findings pertain to Warmbloods only, or even only to certain lines and families. The fact that the 853 
chromosomal regions and the mode of inheritance do not agree between families indicates genetic 854 
heterogeneity for severe EA: depending on the genetic make-up of affected horses, different genes 855 
confer the susceptibility for the disease. It appears that the genetic basis of severe EA is robust, but 856 
remarkably complex. Polygenic complexity, potentially with a larger number of genes that each may 857 
only contribute less than 10 % to the total genetic effects, may make it difficult to discover causative 858 
variants. Nevertheless, the genetics of severe EA has revealed interesting links between severe EA, 859 
allergic skin diseases and susceptibility to intestinal parasites.(159,160) 860 
 861 
Are pertinent biomarkers of equine asthma already available to practitioners and researchers? 862 
– Artur Niedźwiedź 863 
According to the National Institutes of Health, a biomarker is a characteristic that is objectively 864 
measured and evaluated as an indicator of normal biological processes, pathogenic processes or 865 
pharmacologic responses to a therapeutic intervention.(161) In practice, biomarkers include tools and 866 
technologies that can help in understanding the prediction, cause, diagnosis, progression, and 867 
outcome of treatment of a disease. Although BAL cytology has been recognized as the gold standard 868 
for diagnosing respiratory diseases such as EA, currently, sensitive and specific biomarker tests 869 
useful in routine laboratory diagnostics are being sought. A simple biomarker capable of 870 
distinguishing between animals with lower airway infections and those with non-infectious airway 871 
inflammation would be helpful. Although the diagnosis of severe cases of EA is relatively easy, it is 872 
difficult to diagnose cases in remission or horses with a mild form of the disease. Ideally, molecular 873 
biomarkers should reflect a feature of relevant pathological processes. In addition, biomarker 874 
assessment should be easy, low-cost, technically accurate, repeatable and have an acceptable risk. 875 
Therefore, a measurement from easily obtainable body fluids or tissues is preferred, such as blood, 876 
urine, exhaled breath condensates, as opposed to BAL, transbronchial biopsy or lung biopsy.(162) 877 
Several biomarkers are present or altered in the airways or circulation of horses with asthma. 878 
Inflammatory markers such as acute phase proteins and cytokines have been studied as markers of 879 
systemic inflammation. However, the available literature on markers of systemic inflammation in 880 
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horses with severe EA is not well characterized and controversial.(116,163–165) Apart from reports 881 
on differential expression of cytokines during the course of severe EA, only a few acute phase 882 
proteins have been investigated. Haptoglobin is a suitable marker of both acute and chronic systemic 883 
inflammations, whereas high concentrations of serum amyloid A indicate acute inflammation. One 884 
study found no difference in the acute phase protein levels (serum amyloid A, c-reactive protein, 885 
haptoglobin) between horses with mild EA and those with other causes of exercise intolerance.(166) 886 
Another study found elevated haptoglobin concentration in horses with mild EA.(167) 887 
Surfactant protein D is a large multimeric collagenous glycoprotein produced mainly by type II 888 
epithelial cells in the lungs and is also detectable in the serum. Serum surfactant protein D has been 889 
identified as a potential systemic biomarker for some pulmonary diseases in humans, such as 890 
idiopathic interstitial fibrosis and acute respiratory distress syndrome. Elevated serum levels of 891 
surfactant protein D have been detected in horses with mild EA.(167,168) 892 
Circulating immune complexes are proteins that result from an immune response against an organism 893 
or antigens of various origin. In humans, circulating immune complexes are detectable in a variety of 894 
systemic disorders such as autoimmune diseases, allergies and infectious diseases.(169) High levels 895 
of circulating immune complexes have been reported in horses with severe EA.(165) Another study 896 
found circulating immune complexes useful for differentiating healthy vs. severe EA, and monitoring 897 
corticosteroids therapy.(170) 898 
The main group of enzymes responsible for collagen and other protein degradation in the 899 
extracellular matrix are matrix metalloproteinases (MMPs), while tissue inhibitors of 900 
metalloproteinases (TIMPs) lead to fibrosis formation. Collagen is the main structural component of 901 
connective tissue and its degradation is a very important process in development, morphogenesis, 902 
tissue remodeling, and repair. In horses with severe EA, MMPs, TIMPs, and their ratios are useful in 903 
the evaluation of the severity of respiratory disease and in identifying subclinical cases.(91) 904 
Furthermore, MMP-2, MMP-9, TIMP-1, and TIMP-2 are significantly decreased after therapy with 905 
inhaled glucocorticoid therapy.(171) 906 
Exhaled breath condensate is a promising source of biomarkers of lung disease in humans. Exhaled 907 
breath condensate hydrogen peroxide concentration and pH were higher in horses with mild EA, vs. 908 
controls.(69) Additionally, both hydrogen peroxide and pH had a positive association with BAL 909 
neutrophil percentage, while leukotriene B-4 demonstrated a positive association with BAL 910 
eosinophil percentage. Another study characterized the metabolomic profile of tracheal wash and 911 
exhaled breath condensate in healthy horses and those with severe EA.(172) Higher concentrations of 912 
histamine and oxidant agents, such as glutamate, valine, leucine, and isoleucine, as well as lower 913 
levels of ascorbate, methylamine, dimethylamine and O-phosphocholine, were found in the group of 914 
severe EA, compared to healthy controls. 915 
Many biomarkers of EA have been studied — some are already being used in clinical settings, while 916 
others require further studies. However history, clinical evaluation, and BAL still constitute the basis 917 
for diagnosis of EA. 918 
 919 
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How do we standardize immunologic laboratory testing? – Eric Richard 920 
Immune response has mainly been investigated in the airways of horses with severe EA and more 921 
recently mild-moderate EA, while still representing one of the futures direction for research stated in 922 
the 2016 ACVIM Consensus Statement.(3) Such characterization has mostly been performed through 923 
relative mRNA expression of various cytokines in BAL fluid, while several publications also 924 
reported protein concentration in BAL fluid for few cytokines. Various methodologies for cytokine 925 
mRNA expressions have been published (e.g. SYBR Green or Taqman technology, design of primers 926 
and probes, relative quantitation, etc.). 927 
Variation in methodologies may ultimately prevent objective comparisons between reports, as well as 928 
the implementation of prospective, multicenter studies. Such diversity should however not be 929 
considered as a scientific weakness, and methodological homogenization among the various research 930 
groups neither represents a prerequisite nor a final goal to be reached. However, evaluation of the 931 
methodological performances of different research laboratories might represent a relevant goal. In 932 
this manner, implementation of inter-laboratory comparisons based on international standards (e.g. 933 
ISO/IEC 17043 and ISO 13528) warrants further consideration.  934 
Let’s consider for example mRNA expression of two different cytokines by PCR in BALF samples. 935 
As a first and informal procedure, a simple “blind test” could be performed among up to four 936 
different teams. In this procedure, the “reference lab” will provide the three other labs with aliquots 937 
of the same sample(s). Each team will evaluate mRNA expression for these two cytokines based on 938 
their own procedures, and comparisons of the results obtained and agreement among the teams can 939 
be evaluated. This “blind test” might then be repeated on a regular basis, systematically alternating 940 
the ‘reference lab’ within the group. In the end, the procedure will provide an objective evaluation of 941 
the results diversity among the teams, but clearly will not determine whether several teams are more 942 
efficient than others for these specific analyses. 943 
A second and more structured procedure would require the specific synthesis of standards (mRNA 944 
for two different cytokines in this case), and the development/validation of relevant conditioning and 945 
conservation procedures. A similar group of four different labs would first evaluate their ability to 946 
detect and quantify predetermined amounts of analytical standards (evaluation of the detection, not of 947 
the sample extraction, etc.). This step is a necessary preliminary, in the absence of reference methods. 948 
A panel of at least 10 samples (previously calibrated with standards) would then be tested, including 949 
several identical ones (for repeatability) and submitted to the group (including a “self-shipment”) for 950 
testing and further statistical analyses (agreement, etc.). Once the methodological performance of the 951 
lab is considered acceptable for this panel, the procedure might then be repeated with another two 952 
cytokines and so on. In the end, the whole panel of standardized samples might allow the 953 
establishment of a labeling, accessible to any voluntary laboratory involved in equine asthma. 954 
Mandatory considerations about such comparisons are that there is no trap, and this does not 955 
represent an overall examination of laboratories, but simple evaluations of procedures. All labs are 956 
expected to use their methodologies, whether or not the technologies are similar within the group. 957 
Among others, samples conditioning, conservation, shipment and their associated costs will represent 958 
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major issues to be considered, and this should be more broadly associated with virtuous initiatives 959 
such as the Equine Respiratory Tissue Biobank. 960 
 961 
Future research directions in equine asthma: systematic summary of suggestions from final 962 
roundtable discussions – Jacqueline M Cardwell, Melissa Mazan, Laurent Couetil, Renaud 963 
Leguillette, Eric Richard 964 
Several group discussions were conducted during the 2019 Havemeyer Equine Asthma Workshop to 965 
identify future research priorities. Initial rotating small-group topic explorations (pathophysiology, 966 
risk-factors, diagnostic methods and phenotype definition) facilitated by members of the workshop 967 
organizing team, were followed by a final large group “roundtable” discussion of key directions for 968 
future EA research. The discussion was informed by data gathered directly from approximately 30 969 
participants (i.e. all who attended the final roundtable), who were invited to propose up to three short- 970 
or long-term, focused or “big picture”, research topics or ideas that they considered to be key future 971 
research directions. These data were submitted anonymously, during the workshop, as free-text on 972 
paper and loosely arranged into broad categories for further open discussion.  973 
Following the workshop, in order to present an accessible, systematic and non-selective summary of 974 
the ideas proposed by participants, the free-text data were collated in Microsoft Excel for content 975 
analysis using an approach based on recommended methods for quasi-qualitative data.(173,174) The 976 
text was transcribed verbatim and coded at two levels to categorize content into (i) broad topic areas 977 
(Level 1) and (ii) specific subsets of these topics (Level 2). All instances of each Level 1 topic code 978 
were then exported into online software (WordItOut) to create a word cloud (Figure 1), in which the 979 
relative frequencies of occurrence of each topic are represented by font size.  980 
Figure 1: Word Cloud summary of topic areas proposed by workshop participants as key future 981 
directions for equine asthma research 982 
 983 
 984 
 985 
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 987 
 988 
 989 
 990 
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 992 
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Overall, 62 responses were received, each proposing between 1 and 3 research ideas, resulting in a 993 
total of 117 research ideas, which were organized into the 14 broad topic codes presented in the word 994 
cloud. Some research ideas encompassed more than one topic and were identified with multiple codes 995 
to reflect this. Frequencies of occurrence of each code ranged from n=28 for “diagnostics” to n=1 for 996 
“genetics”. 997 
Specific proposed areas of interest in the dominant “diagnostics” category were the development of 998 
improved, non-invasive field diagnostics through the identification of suitable biomarkers, 999 
development of portable lung function tests, improved understanding of relative values of tracheal 1000 
wash in comparison with BAL cytology, or relationships between the two, and identification of gold 1001 
standards for all of these diagnostic modalities. 1002 
Another key topic was phenotype distinction (21 occurrences) – in particular to clarify any distinction 1003 
between mild and moderate EA, and to determine whether or not such a distinction is valuable in terms 1004 
of differing pathophysiology, diagnostic indicators, therapeutics or prognosis.  As with many of these 1005 
proposed topics, phenotype distinction rests on the back of the category “diagnostics” – pointing out a 1006 
self-identified weakness on the part of EA researchers that the goal of identifying the horse with asthma 1007 
so mild that it does not present as respiratory disease per se, continues in many cases to elude us and 1008 
underscores a collective pragmatism that there is little benefit in understanding the fine points if we  1009 
cannot definitively identify the case in the first place.  1010 
Ideas relating to therapeutics (18 occurrences) included investigating the efficacy of different 1011 
treatments including environmental management and any evidence for the value of antibiotics, as well 1012 
as the development of optimal nebulized glucocorticoids, alternatives to corticosteroids, 1013 
immunological treatments, respiratory probiotics, other novel therapeutics (e.g. MARCKS inhibitor 1014 
peptide), and individualized treatments for different endotypes and phenotypes. 1015 
Suggestions relating to pathophysiology (17 occurrences) included furthering our understanding of the 1016 
role of environmental pollutants, of when a physiological response becomes a pathological response 1017 
and of factors influencing progression from mild to severe equine asthma. 1018 
Standardization (11 occurrences) referred in particular to the need to develop or agree on standardized 1019 
diagnostic approaches, including in relation to BAL collection techniques, laboratory processing and 1020 
cytological methods and threshold values, context-specific reference ranges, development of a central 1021 
repository of protocols and improved quality control protocols. A central repository of standard 1022 
protocols was suggested. 1023 
Academic-clinical communication (9 occurrences) was recognized as an area for general improvement. 1024 
Related research suggestions included improving our understanding of the views and practices of field 1025 
clinicians, as well as their perceptions of disease progression and treatment efficacy, particularly in 1026 
regions outside the UK (to build on the Kinnison & Cardwell UK study).(104) This would inform the 1027 
enhancement of multi-directional communication between academia, referral and first opinion clinical 1028 
practice, development of guidelines and apps for field practice and overall improved dialogue and 1029 
engagement. 1030 
Better use of collaborative, epidemiological and longitudinal studies was suggested for many topics 1031 
and included multicenter, cross-country collaborations, more use of the existing tissue bank and the 1032 
initiation of a new Equine Asthma Group.  1033 
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It is recognized that the ideas for research directions generated through this roundtable discussion at 1034 
the end of a 3-day workshop are subject to biases and influences relating to the interests, priorities and 1035 
perceptions of workshop participants. However, by using and describing a systematic method of 1036 
representing the ideas proposed, we have aimed at least to be transparent in our reporting of this. 1037 
Further, longer-term, international discussion and exchange of views will be facilitated by one of the 1038 
key outcomes of this workshop, which was the development of the new Equine Asthma Group. The 1039 
aim of this group is to offer a platform of information for veterinary practitioners and horse owners as 1040 
well as a resource for researchers to collaborate and exchange ideas on the understanding of EA. It was 1041 
suggested that this group could lead some initiatives in line with the proposed areas of interest 1042 
described above. There are plans for this group to develop some guidelines for the diagnosis and 1043 
treatment of equine asthma, including for example the standardization of diagnostic methods, as 1044 
mentioned above.  Development of an Equine Asthma Group website and other communication tools 1045 
are now underway as an internationally collaborative initiative. 1046 
Conclusion 1047 
The 2019 Havemeyer Equine Asthma Workshop has paved the way for a better understanding of this 1048 
many-faceted disease by bringing together researchers and clinicians to identify both the needs of the 1049 
equine industry for effective treatments and at the same time focus researchers on the gaps in 1050 
knowledge and understanding that will facilitate our ability to deliver on these needs. The participants 1051 
made clear the requirement for more accessible, standardized diagnostics that will enable us to 1052 
understand the underlying pathophysiology and identify specific phenotypes and endotypes and thus 1053 
create more targeted treatments or management strategies. By creating an Equine Asthma Group, we 1054 
will have a platform to unify the veterinary practice and research communities through agreed-upon 1055 
research targets and through published and easily accessible guidelines, creating a point of convergence 1056 
for identification of cases that will facilitate research.  1057 
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